ID   hTERT NF1 ipNF95.11b C
AC   CVCL_UI67
SY   ipNF95.11b C; ipNF95.11b "C"; ipNF95.11bC
DR   ABM; T0179
DR   ATCC; CRL-3390
DR   Wikidata; Q94305840
RX   PubMed=27617404;
RX   PubMed=29055717;
RX   PubMed=29893754;
WW   Info; NTAP; -; https://www.n-tap.org/for-researchers/cell-model-systems
CC   Doubling time: ~32.7 hours (ATCC=CRL-3390).
CC   Sequence variation: Gene deletion; HGNC; HGNC:7765; NF1; Zygosity=Heterozygous; Note=Somatic LOH (PubMed=27617404).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; p.Thr586Valfs*18 (c.1756_1759delACTA) (1756delACTA); ClinVar=VCV000186215; Zygosity=Heterozygous; Note=Germline (PubMed=27617404).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:11730; TERT.
CC   Genetic integration: Method=Transduction; Gene=MGI; MGI:88357; Cdk4.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Peripheral nervous system, nerve; UBERON=UBERON_0001021.
CC   Cell type: Schwann cell; CL=CL_0002573.
ST   Source(s): ATCC=CRL-3390; PubMed=27617404
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 13,14
ST   D18S51: 12,15
ST   D19S433: 13,14
ST   D21S11: 29,31.2
ST   D2S1338: 23,24
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 10,12
ST   D8S1179: 10,14
ST   FGA: 22,23
ST   Penta D: 8,11
ST   Penta E: 7,13
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C3273; Neurofibromatosis type 1
DI   ORDO; Orphanet_636; Neurofibromatosis type 1
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_UI68 ! hTERT NF1 ipNF95.11b C/T
OI   CVCL_UI69 ! hTERT NF1 ipnNF95.11c
SX   Male
AG   19Y
CA   Telomerase immortalized cell line
DT   Created: 25-02-19; Last updated: 10-04-25; Version: 13
//
RX   PubMed=27617404; DOI=10.1038/labinvest.2016.88;
RA   Li H., Chang L.-J., Neubauer D.R., Muir D.F. 4th, Wallace M.R.;
RT   "Immortalization of human normal and NF1 neurofibroma Schwann cells.";
RL   Lab. Invest. 96:1105-1115(2016).
//
RX   PubMed=29055717; DOI=10.1016/j.expneurol.2017.10.012; PMCID=PMC6863155;
RA   Kraniak J.M., Chalasani A., Wallace M.R., Mattingly R.R.;
RT   "Development of 3D culture models of plexiform neurofibroma and
RT   initial application for phenotypic characterization and drug
RT   screening.";
RL   Exp. Neurol. 299:289-298(2018).
//
RX   PubMed=29893754; DOI=10.1038/sdata.2018.106; PMCID=PMC5996849;
RA   Ferrer M., Gosline S.J.C., Stathis M., Zhang X.-H., Guo X.-D., Guha R.,
RA   Ryman D.A., Wallace M.R., Kasch-Semenza L., Hao H.-P., Ingersoll R.G.,
RA   Mohr D., Thomas C.J., Verma S., Guinney J.H., Blakeley J.O.;
RT   "Pharmacological and genomic profiling of neurofibromatosis type 1
RT   plexiform neurofibroma-derived Schwann cells.";
RL   Sci. Data 5:180106.1-180106.12(2018).
//